As a follow up to Adam Okun’s blog earlier this week, I wanted to provide more details. With employers and consumers facing rapidly increasing drug costs, the pharmaceutical industry has been the target of significant criticism for its lack of transparency and conflicting incentives. A major point of contention is drug rebates. The problem with… [Read More]
Drug Coalitions Unmasked
There was an interesting recent article published by Axios that’s beginning to expose one of the great mistruths in our industry – that drug purchasing coalitions sponsored by the largest benefits consulting firms save money. As we have been advising clients for years, pricing coalitions sound brilliant in theory but often fail miserably in practice. Theoretically, drugs are a… [Read More]
